Nonchemotherapy drug-induced agranulocytosis in children detected by a prospective pharmacovigilance program

References

• Munshi HG, Montgomery RB. Severe neutropenia: a diagnostic approach. West J Med. 2000;172:248–252.
   PubMedGoogle Scholar
• Strom BL, Carson JL, Schinnar R, et al. Descriptive epidemiology of agranulocytosis. Arch Intern Med. 1992;152(7):1475–1480.
   PubMedGoogle Scholar
• Braden CD, Besa EC. Neutropenia. Clinical Update. Retrieved from http://www.emedicine.com/MED/topic82.htm. August 28, 2015
   Google Scholar
• Kaufman DW, Kelly JP, Jurgelon JM, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl. 1996;60:23–30.
   PubMedGoogle Scholar
• Böttiger LE, Böttiger B. Incidence and cause of aplastic anemia, hemolytic anemia, agranulocytosis and thrombocytopenia. Acta Med Scand. 1981;210:475–479.
   Google Scholar
• Danielson DA, Douglas SW 3rd, Herzog P, et al. Drug-induced blood disorders. JAMA. 1984;252:3257–3260.
   PubMed Web of Science ®Google Scholar
• van der Klauw MM, Goudsmit R, Halie MR, et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med. 1999;159:369–374.
   PubMedGoogle Scholar
• Rawson NS, Harding SR, Malcolm E, et al. Hospitalizations for aplastic anemia and agranulocytosis in Saskatchewan: incidence and associations with antecedent prescription drug use. J Clin Epidemiol. 1998;51:1343–1355.
   PubMed Web of Science ®Google Scholar
• Ibáñez L, Juan J, Pérez E, et al. Agranulocytosis associated with aprindine and other antiarrhythmic drugs: an epidemiological approach. Eur Heart J. 1991;12:639–641.
   Google Scholar
• Strom BL, Carson JL, Schinnar R, et al. Nonsteroidal anti-inflammatory drugs and neutropenia. Arch Intern Med. 1993;153:2119–2124.
   PubMedGoogle Scholar
• Laporte JR, Capellà D, Juan J. Agranulocytosis induced by cinepazide. Eur J Clin Pharmacol. 1990;38:387–388.
   PubMed Web of Science ®Google Scholar
• Ibáñez L, Ballarín E, Pérez E, et al. Agranulocytosis induced by pyrithyldione, a sedative hypnotic drug. Eur J Clin Pharmacol. 2000;55:761–764.
   Google Scholar
• Ibáñez L, Ballarín E, Vidal X, et al. Agranulocytosis associated with calcium dobesilate clinical course and risk estimation with the case-control and the case-population approaches. Eur J Clin Pharmacol. 2000;56:763–767.
   Google Scholar
• Ibáñez L, Vidal X, Ballarín E, et al. Population-based drug-induced agranulocytosis. Arch Intern Med. 2005;165:869–874.
   Google Scholar
• Lee YH, Lee HB, Kim JY, et al. Antibiotic-induced severe neutropenia with multidrug-dependent antineutrophil antibodies developed in a child with Streptococcus pneumoniae infection. J Korean Med Sci. 2009;24:975–978.
   PubMed Web of Science ®Google Scholar
• Stroncek DF. Drug-induced immune neutropenia. Transfus Med Rev. 1993;7:268–274.
   PubMedGoogle Scholar
• Ramirez E, Carcas AJ, Borobia AM, et al. A pharmacovigilance program from laboratory signals for the detection and reporting of serious adverse drug reactions in hospitalized patients. Clin Pharmacol Ther. 2010;87:74–86.
   PubMed Web of Science ®Google Scholar
• Organic law 15/1999 of 13 December 1999 on the Protection of Personal Data (BOE núm. 298, de 14-12-1999, pp. 43088–43099.
   Google Scholar
• ICH Guideline on E2D Postapproval Safety Data Management: Definitions and Standards for Expedited Reporting. London, 20 November 2003 CPMP/ICH/3945/03. Available at: http://eudravigilance.ema.europa.eu/human/ichAndEtransmission03.asp. Accessed August 28, 2015.
   Google Scholar
• Capellá D, Laporte JR. The spontaneous reporting of adverse drug reactions. In: Laporte, JR, Tognoni G, eds. Principios de Epidemiología del Medicamento. 2nd ed. Barcelona, ESP: Masson-Salvat; 1993:147–170.
   Google Scholar
• Boxer LA. How to approach neutropenia. Hematol Am Soc Hematol Educ Program. 2012;2012:174.
   PubMedGoogle Scholar
• Jiménez Gómez J, Polo Miquel B, Donat Aliaga E. Acute hepatic failure. In: ERGON, eds. Diagnostic-therapeutic Protocols of Gastroenterology, Hepatology and Nutrition Pediatric. 1st ed., Madrid, Spain, 2010:197–205.
   Google Scholar
• Jimenez Gomez J, Polo Miquel B, Donat Aliaga E. [Acute hepatic failure]. In: Spanish Society of Gastroenterology, Hepatology and Pediatric Nutrition (ed.). Diagnostic-Therapeutic Protocols of Gastroenterology, Hepatology and Nutrition Pediatric, 1st edn. ERGON, Madrid, Spain, 2010;197–205.
   Google Scholar
• Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254. Erratum in: Ann Intern Med. 2008;149(7):519.
   PubMed Web of Science ®Google Scholar
• Spanish Agency for Medicines and Health Products. Medicines Online Information Center – CIMA). http://www.aemps.gob.es/cima/fichasTecnicas.do. Accessed 28 August 2015.
   Google Scholar
• British Electronic Medicines Compendium (eMC) as summary of product characteristics (SPC). http://www.medicines.org.uk. Accessed on 28 August 2015
   Google Scholar
• FDA database of drugs as summary of product characteristics (SPC). Available as item Drugs@FDA at http://www.fda.gov. Accessed August 28, 2015.
   Google Scholar
• Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991;266:2847–51. Erratum in: JAMA 1992; 267:1922.
   Google Scholar
• Bates DW, O'Neil AC, Boyle D, et al. Potential identifiability and preventability of adverse events using information systems. J Am Med Inform Assoc. 1994;1:404–411.
   PubMed Web of Science ®Google Scholar
• Lee YH, Lee HB, Kim JY, et al. Antibiotic-induced severe neutropenia with multidrug-dependent antineutrophil antibodies developed in a child with Streptococcus pneumoniae infection. J Korean Med Sci. 2009;24:975–978.
   PubMed Web of Science ®Google Scholar
• Kaufman DW, Kelly JP, Levy M, Shapiro S, eds. The Drug Etiology of Agranulocytosis and Aplastic Anaemia. New York: Oxford University Press Inc, 1991;148–158.
   Google Scholar
• Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. JAMA. 1986;256:1749–1757.
   PubMedGoogle Scholar
• Kurtz JE, Andres E, Maloisel F, et al. Drug-induced agranulocytosis in older people. A case series of 25 patients. Age Ageing. 1999;28:325–326.
   PubMed Web of Science ®Google Scholar
• Tavassoli N, Duchayne E, Sadaba B, et al. Detection and incidence of drug-induced agranulocytosis in hospital: a prospective analysis from laboratory signals. Eur Clin Pharmacol. 2007;63:221–228.
   Web of Science ®Google Scholar
• Spain DM, Clark TB. A case of agranulocytosis occurring during the course of penicillin therapy. Ann Intern Med. 1946;25:732.
   PubMed Web of Science ®Google Scholar
• Anti-infective drug use in relation to the risk of agranulocytosis and aplastic anemia. A report from the International Agranulocytosis and Aplastic Anemia Study. Arch Intern Med. 1989;149:1036–1040.
   PubMedGoogle Scholar
• Andrès E, Maloisel F, Kurtz JE, et al. Modern management of non-chemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature. Eur J Intern Med. 2002;13:324–328.
   Google Scholar
• Wiholm BE, Emanuelsson S. Drug-related blood dyscrasias in a Swedish reporting system, 1985–1994. Eur J Haematol Suppl. 1996;60:42–46.
   PubMedGoogle Scholar
• Scheetz MH, McKoy JM, Parada JP, et al. Systematic review of piperacillin-induced neutropenia. Drug Saf. 2007;30:295–306.
   PubMed Web of Science ®Google Scholar
• Juliá A, Olona M, Bueno J, et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol. 1991;79:366–371.
   Google Scholar
• Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol. 2002;58:265–274.
   PubMed Web of Science ®Google Scholar
• Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol. 2009;84:428.
   PubMed Web of Science ®Google Scholar
• Johnston A, Uetrecht J. Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis. Exp Opin Drug Metab Toxicol. 2015;11:243.
   PubMed Web of Science ®Google Scholar
• Takakusa H, Masumoto H, Yukinaga H, et al. Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity. Drug Metab Dispos. 2008;36:1770–1779.
   PubMed Web of Science ®Google Scholar
• Christie DJ. Specificity of drug-induced immune cytopenias. Transfus Med Rev. 1993;7:230.
   PubMedGoogle Scholar
• Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol. 2009;84:428.
   PubMed Web of Science ®Google Scholar
• Guest I, Uetrecht J. Drugs toxic to the bone marrow that target the stromal cells. Immunopharmacol. 2000;46:103–112.
   PubMed Web of Science ®Google Scholar
• Pecaric-Petkovic T, Didichenko SA, Kaempfer S, et al. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood. 2009;113:1526–1534.
   PubMed Web of Science ®Google Scholar
• Levy M, Kelly JP, Kaufman DW, et al. Risk of agranulocytosis and aplastic anemia in relation to history of infectious mononucleosis: a report from the International Agranulocytosis and Aplastic Anemia Study. Ann Hematol. 1993;67:187–190.
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107–1116.
   PubMed Web of Science ®Google Scholar
• Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf. 1993;9(1):51–59.
   PubMed Web of Science ®Google Scholar
• Liu L, Chen L, Zhang YH, et al. Analysis and prediction of drug-drug interaction by minimum redundancy maximum relevance and incremental feature selection. J Biomol Struct Dyn. 2016;4:1–18.
   PubMedGoogle Scholar
• Savvidaki E, Kazakopoulos P, Papachristou E, et al. Replacement of mycophenolate acid with everolimus in patients who became neutropenic after renal transplant. Exp Clin Transplant. 2014;12:31–36.
   PubMed Web of Science ®Google Scholar